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The observation that depletion or inhibition of regulatory T cells (Tregs) unleashes efficient antitumor effector immune responses
that can lead to tumor eradication in mice has opened new perspectives for the development of cancer immunotherapy. The quality
and overall efficiency of the effector immune responses induced in the absence of Tregs seem to depend on multiple factors that
determine the result of a battle involving effector T cells (Teffs), Tregs and tumor cells. In this study, we investigated the quality of
tumor-associated antigens (TAAs) as one such factor. We show that the presence of a strong dominant antigen is required for the
induction of effector responses capable of tumor eradication in the absence of Tregs. The sole addition of a dominant antigen on
tumor cells does not change tumor growth in unmanipulated mice, but improves tumor eradication rate from a few to almost 100%
in the absence of Tregs. This eradication can be shown to result from the recruitment and activation of specific Teffs recognizing this
antigen. We also show that the presence of such dominant antigens has the side effect of restricting the breadth of the immune
response to other TAAs, which could favor the generation of escape mutant by tumor editing. Taken together, our results highlight
the potential, and some requirements for cancer immunotherapy based on Treg depletion. They also show that, ultimately, tumor
fate depends on multiple factors that should all be taken into consideration for the design of more efficient immunotherapy.
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Introduction
It is now well documented that during immune responses
against cancer, effector and regulatory T cells (Teffs and
Tregs, respectively) coexist in the tumor environment and
draining lymph nodes (dLNs).
1–3 In vivo depletion/
inhibition of Tregs by anti-CD25 antibody (Ab) injection
during the very first days of tumor growth, leads to
tumor-reactive Teff activation and induces a potent
antitumor immune response that can lead to tumor
eradication. It is noteworthy that this has been observed
in most if not all tumor models, in various genetic
backgrounds and with tumor cells of various origins, thus
indicating that it is a general property of antitumor
immune responses.
4–6
Interestingly, tumor eradication on Treg control occurs
with various frequencies according to the tumor models,
from all animals being cured in some models to only a
delay in tumor growth in others. For instance, the B16F10
melanoma growth in C57BL/6 mice is only delayed
by Treg depletion,
7,8 whereas Treg depletion in BALB/c
mice induces the rejection of the 4T1 adenocarcinoma in
50–80% of mice
6,9 and of AB1-HA mesothelioma in close
to 100% of mice, as presented in this study.
It is striking that, for each tumor, only a proportion of
the treated animals is able to reject the tumors, when
considering that in such experiments, mice have the same
genetic background, the same polyclonal immune cell
repertoire, are kept in the same environmental conditions
in animal facilities and receive the same batch of tumor
cells. These results suggest that tumor fate is the uncertain
result of a battle, in which the characteristic of the
players—tumor cells, Tregs and Teffs—are key para-
meters. Even in the absence of Tregs, the efficacy of Teffs
to eradicate tumor cells is ‘border line,’ leading to either
rejection or just a slower tumor growth.
In this study, we aimed at evaluating the importance of
the nature of tumor-associated antigens (TAAs) in the
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www.nature.com/cgtsignificance of these observations. For this, we compared
the growth of tumor cells differing only by the expression
of a single TAA known to induce excellent cellular
immune responses. We chose the hemagglutinin (HA) of
Influenza virus because: (1) HA is a potent immunogen
for both BALB/c and C57BL/6 mice; vaccination against
HA is known to induce strong cytotoxic T-lymphocyte
responses in these mice
10 and (2) there exists a set of
transgenic mice that are interesting tools for studying
anti-HA immune responses.
11,12 SFE mice express a HA-
specific transgenic T-cell receptor (TCR) and can serve as
a source of anti-HA Teffs. Although the SFE-TCR is
primarily major histocompatibility complex class-II re-
stricted and expressed on effector CD4þ cells, it is also
expressed and functional on cytotoxic CD8þ T cells of
these mice.
12 It is noteworthy that the transgenic TCR of
SFE mice can be detected with both a specific monoclonal
Ab and an even more sensitive quantitative PCR assay.
Besides, InsHA transgenic mice express HA under the control
of the insulin promoter; in these mice, HA is thus an auto-
antigen expressed in the pancreas. Using the insulin promoter
for HA expression, it has been shown that HA is also
expressed in medullary thymic epithelial cells
13 by an
autoimmune regulator-dependant mechanism;
14 similarly,
HA-specific Teffs are deleted,
15,16 whereas HA-specific
Tregs are generated during thymocyte differentiation in
InsHA mice.
17 Accordingly, TCR-HA-specific Tregs, but
not TCR-HA-specific Teffs, can be detected in the pancreatic
lymph nodes (LNs) of InsHA mice.
We thus compared the growth of the malignant
asbestos-induced AB1 mesothelioma, and its AB1-HA
derivative, in different experimental conditions. Our
results show that the expression of a potent TAA by
tumor cells is essential for tumor eradication when Tregs
are depleted. However, it also strongly biases the response
toward this antigen, hampering the response to additional
TAAs. This could be detrimental for an efficient
antitumoral response as it could favor the emergence of
immune escape mutant by tumor editing.
Materials and methods
Animals
Female BALB/c mice, 6–8-weeks of age, were obtained
from Elevage Janvier (Le Genest St Isle, France). InsHA
and SFE TCR-HA mice were bred in our animal facility.
Mice were housed in filter-topped cages under specific
pathogen-free conditions in our animal facilities. All mice
were treated in accordance with the European Union
guidelines for animal experimentation.
Cell lines and tumor assays
The BALB/c 4T1 mammary carcinoma and its 4T1-HA
derivative (obtained in our laboratory) expressing the
murine influenza HA were cultured in Iscove’s modified
Dulbecco’s medium (IMDM) (Gibco–Invitrogen, Cergy
Pontoise, France) supplemented with 10% fetal calf
serum (Gibco–Invitrogen) and 1% gentamycin (Gibco–
Invitrogen).
The BALB/c AB1 malignant mesothelioma,
18 and its
AB1-HA derivative,
1 were cultured in RPMI (Gibco–
Invitrogen) complemented with 10% fetal calf serum,
2m ML-glutamine (Gibco–Invitrogen), 100Units per ml of
penicillin–streptomycin (Gibco–Invitrogen) and 50mM
2-mercaptoethanol. These AB1 and AB1-HA cell lines
were a generous gift from Dr Bernadette Scott (CFGHD,
MIMR, Clayton, Victoria, Australia). All cell lines were
mycoplasma free. For in vivo experiments, 1 10
5 (4T1
and 4T1-HA) or 5 10
5 (AB1 and AB1-HA) tumor cells
were injected subcutaneously into the right flank of
the mice. The right inguinal LN was used as the dLN.
The contralateral brachial LN was used as the non-dLN.
Tumor-inoculated mice were killed when average tumor
diameters reached 15–20mm. Tumor volume (mm
3) was
determined by measuring perpendicular tumor diameters
using Vernier calipers (V¼(L l
2)/2).
Antibodies and flow cytometry analysis
LN cells were obtained after a mechanical dissociation
and were then stained with saturating amounts of
combinations of the following mAbs: Alexa700-labeled
anti-CD4, PerCp-labeled anti-CD8, PE (phycoerythrin)-
labeled anti-CD62L, APC-labeled anti-CD25 and PE-Cy7-
labeled CD44 (all from BD Biosciences, Pont de Claix,
France). Labeling with the anti-clonotypic mAb (clone 6.5)
specific to TCR-HA was revealed by a biotin anti-rat IgG2b
mAb and streptavidin-PerCp (BD Pharmingen). Intracellular
labeling of transcription factor Foxp3 (forkhead/winged-
helix protein 3) by anti-Foxp3 conjugated to PE or Pacific
Blue (FJK-16s, e-Bioscience, San Diego, CA) was performed
according to the manufacturer’s recommendations. Isotype-
irrelevant mAbs were used as controls.
Lymphocytes were analyzed using a FACSCalibur
(Pont de Claix, France) or LSR-II. Further analyses were
performed with FlowJo (Tree Star, Ashland, OR) software.
In vivo depletion of CD4þ CD25þ T cells
Treg in vivo depletion was performed by intraperitoneal
injection of 125mg of an anti-CD25 monoclonal Ab
(PC61) the day before tumor inoculation. This induces a
480% transient depletion of CD25high cells for B4
weeks in LNs of normal mice.
Adoptive transfer of HA-specific naive Teffs or antigen-
experienced Teffs
Naive Teffs were magnetically depleted of CD25þ cells
and then were sorted on the CD44low marker on a
FacsARIA (Pont de Claix, France) cytometer, with a
purity of 498%. Antigen-experienced HA-specific Teffs
were generated in vivo by subcutaneous immunization
of SFE mice on the right (50mg) and left (50mg) flanks
and at the base of the tail (100mg) with HA peptide in
Incomplete Freund’s Adjuvant (Sigma-Aldrich, Lyon,
France). Mice were killed 2 months later and popliteal,
inguinal LNs and spleen were harvested. Total cells are
enriched in antigen-experienced Teffs of HA specificity
(data not shown). These cells were then infused intra-
venously in BALB/c mice then challenged with AB1-HA
tumor cells at day 0.
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AB1, AB1-HA or 4T1, 4T1-HA tumor cells were injected
subcutaneously in InsHA and BALB/c mice at day 0 with
or without PC61 depletion of Tregs. Fifteen days later,
mice were killed and tumor dLNs, non-dLNs and tumor
intra lymphocytes were harvested as well as pancreatic
LN from InsHA mice. Total mRNA was prepared from
cells using TRIzol Reagent (Invitrogen) and phenol chloro-
form extraction. Reverse transcription PCR was performed
to synthesize cDNA for PCR analysis. TCR-HA cDNA in
each sample was quantified by real-time quantitative PCR
(Applied Biosystems, Courtaboeuf, France) as described
previously.
19
Statistical methods
Statistical analyses of survival curves were performed
using log-rank (Mantel–Cox) test. Comparisons of tumor
growth curve were performed day per day using two-
tailed t-test. We evaluated statistical significance using
GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego, CA, http://www.graphpad.com).
Results
HA behaves as a potent TAA that elicits efficient effector
responses in the absence of Tregs
To investigate the importance of the quality of TAAs in
mounting effector responses in the presence or absence of
Tregs, we used the AB1 mesothelioma and its cloned
AB1-HA derivative that express the HA of the Influenza
virus.
1,18 When unmanipulated mice are subcutaneously
inoculated with the same amount of AB1 or AB1-HA
tumor cells (5 10
5 per mice), tumors grew in all the
animals with similar kinetics for both tumors (Figure 1a).
In contrast, Treg depletion has a markedly different effect
on these tumors. A single injection of the PC61 anti-CD25
Ab 1 day before tumor challenge led to a rejection rate of
85% for AB1-HA tumor cells, compared with only 10%
for AB1 tumor cells (Figure 1b). Thus, as it has been
documented that Treg depletion unleashes antitumor
Teffs, this suggests that the presence of HA led to the
development of better effector responses.
To actually show that anti-HA effector responses were
responsible for AB1-HA rejection, and to rule out that the
different tumor outcome was due to hidden differences
between the two different tumor cell clones, we repeated
these experiments in InsHA transgenic mice. These mice
lack anti-HA Teffs that are deleted during thymic differ-
entiation. When AB1-HA tumor cells are injected in Treg-
depleted InsHA mice, the percentage of survival decreases
f r o m7 5 %i nn o r m a lm i c et o0 %i nI n s H Am i c e( F i g u r e2 a ) .
Recruitment of HA-specific Teffs in the dLNs of
Treg-depleted AB1-HA bearing mice
To further show that the difference in AB1/AB1-HA
tumor rejection rates in Treg-depleted mice is due to the
effector responses mounted against HA, we quantified
HA-specific T cells in tumor-bearing mice using a novel
TCR-specific quantitative PCR,
19 which detects the
immunodominant HA-specific TCR that was used to
generate SFE TCR-transgenic mice.
12 In SFE mice, the
transgenic TCR is major histocompatibility complex-II
restricted and mostly expressed on CD4þ Teffs, although
functional major histocompatibility complex-II-restricted
CD8þ killer T cells are also generated.
12 BALB/c and
InsHA mice, Treg-depleted or not, were challenged with
AB1-HA or AB1 tumor cells. Tumor dLNs and non-
dLNs were harvested, and the relative proportion of HA-
specific T cells expressing the SFE TCR was determined
by quantitative PCR (Figure 2b).
Compared with the basal levels of HA-specific cells that
can be detected in controls, that is, LNs of AB1 tumor-
bearing BALB/c mice, the frequency of HA-specific T cells is
increased only in the dLNs of Treg-depleted BALB/c mice
challenged with AB1-HA tumors. This indicates that HA-
specific Teffs are indeed recruited by the HA expressing
tumor, but only upon the relief of a Treg-mediated blockage.
In contrast, in InsHA mice in which HA is a self-
antigen and the SFE TCR is thus expressed on Tregs,
19
Figure 1 HA behaves as a potent tumor-associated antigen that
elicits efficient effector responses in the absence of Tregs. (a) Six-
week-old BALB/c mice were injected s.c. with 5 10
5 AB1-HA (black
line) or AB1 (gray line) tumor cells at day 0 (n¼5 in each group).
Graph shows the tumor volume growth (mm
3) of each tumor line.
One representative of 45. (b) Six-week-old BALB/c mice were
injected s.c. with 5 10
5 AB1-HA (n¼12, circle) or AB1 (n¼12,
square) tumor cells at day 0 after Treg depletion by a single injection
i.v. of 125mg PC61 at day  1( n¼10 in each group). Graph shows
the tumor volume growth (mm
3) of each tumor line at day 25 in the
absence of Tregs. AB1-HA tumor volumes were statistically different
from AB1 tumor volumes (***P¼0.0006, with an unpaired t-test).
Five independent experiments were conducted.
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in the dLNs of mice receiving AB1-HA tumor cells, and
this detection is abolished in PC61-treated mice. In this
setting, this reveals the recruitment of self-antigen-specific
Tregs by the tumor. Similar results were observed using
4T1-HA tumor cells (data not shown).
Taken together, HA expression on tumor cells recruits
Teffs in normal BALB/c mice, whereas it recruits Tregs in
InsHA mice.
Only antigen-experienced anti-HA Teffs are capable of
eradicating HA tumors in the presence of Tregs
We asked whether the presence of a strong TAA such as
HA could make the tumor cells good targets for
adoptively transferred Teffs when Tregs are present, a
usual setting of cancer immunotherapy protocols. For
this, we first injected naive anti-HA-specific T cells
obtained from TCR-HA SFE-transgenic mice to mice
challenged with AB1-HA tumor cells. Treg-depleted cells
from SFE mice were sorted on the basis of the CD44low
expression and then injected at increasing doses 1 day
before an AB1-HA challenge. This resulted in a delay in
tumor growth, and similarly prolonged survival, indicat-
ing some contribution of the injected cells to the Treg/Teff
battle. However, no tumor rejection could be observed,
even after the injection of up to 9 10
6 naive HA-specific
cells (Figures 3a and b).
We next investigated whether activated/memory HA-
specific Teffs could better reject HA tumor cells in the
presence of Tregs. We thus collected Teffs from SFE
TCR-HA mice that had been immunized with the HA
peptide and were consequently enriched in HA-specific
memory Teffs (data not shown and Darrasse-Jeze et al.
19)
and then injected them into AB1-HA tumor-bearing mice.
We observed that antigen-experienced Teffs efficiently
rejected AB1-HA (Figures 3c and d) but not AB1 tumor
cells (data not shown).
Expression of the immunodominant HA prevents the
development of a broader response to additional tumor
antigens
We next asked whether the effector response against HA-
expressing tumor was essentially HA directed or also
directed against other tumor antigens. To answer this
question, Treg-depleted BALB/c mice were first chal-
lenged with AB1-HA tumor cells. Mice that rejected the
first tumor and survived were rechallenged 2 months later
with either AB1-HA or AB1 tumor cells, or with the 4T1
adenocarcinoma or its 4T1-HA derivative (Figure 4a, top
and bottom). It is noteworthy that at the time of the
second challenge, these mice have normal Treg number
and function.
20 We observed that all mice rejected the
second AB1-HA tumor challenge (100%), whereas AB1
tumor cells were rejected less efficiently (66% survival). In
addition, 4T1 tumor cells could not be rejected (0%),
unless they expressed HA (33% survival). Thus, the
immunization against AB1-HA tumor cells in the absence
of Tregs drives not only a predominant HA-specific
response but also a response to additional AB1-associated
tumor antigen(s).
We also compared the ability of BALB/c mice that
survived a first challenge with AB1 or AB1-HA tumor
cells performed after Treg depletion, to reject a second
challenge with 4T1 tumor cells (Figure 4b). AB1-HA-
cured mice are poorly able to reject 4T1 tumor (33% in
Figure 4b and 0% in Figure 4a). In contrast, 4T1 tumor
cells were rejected by 100% of AB1-cured mice. This
result shows that 4T1 and AB1 express shared antigens,
which could represent efficient targets of an antitumor
response after immunization. In the presence of an
immunodominant TAA such as HA, the immune
response against the non-HA tumor antigens is masked
or at least reduced. All these results are recapitulated in
Table 1.
Figure 2 Recruitment of HA-specific effector T cells in the draining
lymph node of Treg-depleted AB1-HA bearing BALB/c mice. (a) Six-
week-old BALB/c (n¼8, black line, circle) or 2-month-old InsHA
(n¼7, gray line, square) mice were depleted of Tregs by a single
injection of 125mg PC61 at day  1 and subsequently injected s.c.
with 5 10
5 AB1-HA or AB1 tumor cells at day 0. Graph shows the
Kaplan–Meyer survival curves of mice in the absence of Tregs. The
survival of BALB/c mice was statistically different from the survival of
InsHA mice (**P¼0.0017, with a log-rank (Mantel–Cox) test). (b)
InsHA mice (n¼4) of 6 weeks of age received 5 10
5 AB1-HA
tumors s.c. Age-matched BALB/c mice (n¼4) were injected s.c. with
5 10
5 AB1-HA or AB1 tumor cells at day 0. The mice injected with
AB1-HA were separated into two groups and treated or not with a
single injection of 125mg PC61 at day  1 for Treg depletion. þ or  
refers to PC61 treatment or not, respectively. Normal BALB/c LN and
InsHA pancreatic LN mice were used as negative and positive
controls, respectively. At day 15, mice were killed and the tumor
draining lymph nodes were harvested. mRNA was extracted, cDNA
was synthesized and a TCR-HA TS-Q-PCR was performed. Graph
shows the relative quantity of TCR-HAþ cells in each lymphoid
organs at day 15. Data are representative of three experiments using
two tumor lines AB1-HA and 4T1-HA.
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Cancer Gene TherapyFigure 3 Only antigen-experienced anti-HA effector T cells are capable of eradicating HA tumors in the presence of Tregs. (a, b) Six-week-old
BALB/c mice were injected i.v. with PBS (n¼4, black line) or graded quantities of naive CD25  CD44low TCR-HA T cells from CMH-II restricted
SFE transgenic mice: 1 10
6 (n¼7, light gray line), 3 10
6 (n¼8, gray line) or 9 10
6 (n¼6, dark gray line) cells at day  1 and 5 10
5 AB1-HA
(s.c.) at day 0. Graphs show (panel a), the Kaplan–Meyer survival curves and (panel b), the tumor volume growth curves (mm
3). The treated
groups were statistically different from the PBS-treated group (***P¼0.0005, ***P¼0.0002, ***P¼0.0001, respectively, with a log-rank (Mantel–
Cox) test). (c, d) TCR-HA transgenic mice were immunized in vivo s.c. with HA peptide in IFA. Two months later, mice were killed and the spleen
and inguinal/political lymph nodes were harvested. Six-week-old BALB/c mice were injected s.c. with 5 10
5 AB1-HA at day 0 and i.v. with
15 10
6 effector T cells from immunized TCR-HA mice (n¼5, gray line), containing B3 10
6 memory TCR-HA Teffs, or PBS (n¼5, black line)
at day 0. Graphs show (panel c), the Kaplan–Meyer survival curves and (panel d), the tumor volume growth curves (mm
3). The treated group was
statistically different from the PBS-treated group (*P¼0.0157, with a log-rank (Mantel–Cox) test.
Figure 4 Expression of the immunodominant HA prevents the development of a broader response to additional tumor antigens. (a) Six-week-
old BALB/c mice were depleted of Tregs by a single injection of 125mg PC61 and subsequently injected s.c. with 5 10
5 AB1-HA tumor cells
as in Figure 1. Mice that had rejected the first tumor and survived were rechallenged s.c. 2 months later with 5 10
5 AB1 (gray line) or AB1-HA
(black line) or 1 10
5 4T1 (hatched gray line) or 4T1-HA (hatched black line) tumor cells (n¼3 in each group). Graphs show top, the
Kaplan–Meyer survival curves and bottom, the tumor volume growth curves (mm
3). (b) Six-week-old BALB/c mice were depleted of Tregs by a
single injection of 125mg PC61 at day  1 and subsequently injected s.c. with 5 10
5 AB1-HA (black line) or AB1 (gray line) tumor cells at day 0
(n¼3 in each group). Mice that had rejected the first tumor and survived were rechallenged 2 months later with 10
5 4T1 tumor cells, as well as
age-matched naive mice as a control (n¼2, not shown). Graph shows the tumor volume growth curves (mm
3).
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non-dominant TAA can be overcome by repeated immu-
nization (Figure 5). BALB/c mice that survived a first
AB1-HA challenge after Treg depletion were rechallenged
twice with AB1-HA tumor cells. At each rechallenge,
AB1-HA tumor cells were efficiently rejected without any
intervention. When these mice were finally challenged
with 4T1 tumor cells, they were all able to reject 4T1
tumor cells (Figure 5). This indicates that repeated
immunizations in the presence of the immunodominant
antigen nevertheless boosted the response to non-dominant
tumor antigens.
Discussion
Despite overall disappointing results so far, immunother-
apy of cancer still holds strong rationale and great
potential.
21–23 Indeed, it remains very attractive to use the
patients’ own immune system to specifically attack and
destroy cancer cells, a specific process that could be both
very efficient and safer than chemotherapy.
24,25 However,
the true potential of immunotherapy is likely depending
on (1) the expression by tumor cells of enough antigens
that could be the target of immune effector cells and (2)
the existence and proper activation of a large enough
repertoire of Teffs recognizing these antigens. The
discovery of a large array of TAAs,
26,27 notably using
cloned patients’ Teffs,
28 provided a rationale foundation
for immunotherapy. However, the numerous attempts at
generating therapeutic immune responses in cancer
patients, generated only very few positive responses and
rather pessimistic views on the real potential of cancer
immunotherapy.
23 Optimism renewed with the realization
that, in mice, depletion of Tregs could unleash effector
responses that could lead to tumor eradication. Inciden-
tally, these experiments showed that in most settings there
exist both and enough antigens on the tumor cells and
specific Teffs to obtain tumor eradication. This opened a
new era of immunotherapy, which incorporates strategies
to block Treg responses.
4,5,29–34 However, Treg-depletion
effects on tumor growth ranged from full eradication to
only a slow down of tumor progression; this led us to
investigate the importance of target antigens for effector
immune responses in the absence of Tregs.
Antigen quality and the efficiency of antitumor immune
responses in the absence of Tregs
Our results clearly indicate that the expression of a potent
TAA is the key to induce effector responses capable of
eradicating tumor cells. It is remarkable that the sole
expression of HA turns from 0–15% to 80–100%, the
frequency of tumor rejection in the absence of Tregs
(Figure 1). We showed that this is clearly due to the sole
presence of the HA antigen. Indeed, the 80–100%
frequency of tumor rejection in the absence of Tregs in
BALB/c mice is reverted back to 0–10% in InsHA mice
that cannot mount anti-HA effector immune responses
Table 1 Rejection rate of each tumor in a first or second challenge
First challenge PC61 % Rejection Second
challenge
% Rejection
AB1-HA   0( n¼8)
AB1   0( n¼8)
4T1HA   0( n¼8)
4T1   0( n¼8)
AB1-HA + 83.3 (n¼12)
AB1 + 16.7 (n¼12)
4T1HA + ND
4T1 + 60 (n¼10)
AB1-HA + AB1-HA 100 (n¼6)
AB1-HA + AB1 66 (n¼3)
AB1-HA + 4T1HA 33 (n¼3)
AB1-HA + 4T1 16.7 (n¼6)
AB1 + 4T1 100 (n¼3)
ND, not defined.
  Indicates no PC61 treatment.
+ Indicates with PC61 treatment.
Numbers are expressed in percentages.
Data representative of one experiment among five.
Figure 5 Repeated tumor challenges foster non-HA immune response. Six-week-old BALB/c mice were injected i.v. with 125mg PC61 at day
 1 to deplete Tregs (n¼5, gray line) or PBS (n¼5, black line) and subsequently injected s.c. with 5 10
5 AB1-HA tumor cells at day 0. Mice that
had rejected the first tumor (4/5) were rechallenged s.c. 1.5 months later with 5 10
5 AB1-HA, as well as 4 naive age-matched BALB/c mice (left
insert). Mice that rejected the second tumor (4/4) were again rechallenged 1.5 months later with 5 10
5 AB1-HA as well as 4 naive age-matched
BALB/c mice (middle insert). Mice that rejected the third AB1-HA tumor (4/4) were rechallenged 1 month later with 1 10
5 4T1 as well as 4 naive
age-matched BALB/c mice (right insert). Graphs show the tumor volume growth (mm
3).
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that InsHA mice have a large pool of HA-specific Tregs,
which is an autoantigen in this mouse background, and
that could change the balance between Teffs and Tregs
numbers in this context. Indeed, we showed that Treg
number is not limiting in the Teffs/Tregs battle inasmuch
that the injection of extremely high numbers of CD25 
CD44low naive T cells does not significantly affect
tumor growth in an otherwise nonmanipulated setting
(Figure 3a). Thus, the poor tumor eradication rate in
InsHA mice can be attributed to the lack of anti-HA
Teffs.
Nevertheless, the quality of the antigen is not the only
factor determining tumor fate in the absence of Tregs.
HA-sensitized mice that have developed an excellent
memory attested by their ability to eradicate AB1-HA
tumor cells in 100% of the cases, could only eradicate
33% of 4T1-HA tumors (Figure 4a). Thus, the global
efficiency of the immune responses is likely multipara-
metric, but requires potent antigens.
Antigen quality and the efficiency of antitumor immune
responses in the presence of Tregs
The expression of a potent TAA that can trigger very
efficient effector responses in the absence of Tregs is
clearly not sufficient for gaining tumor eradication in
their presence. AB1-HA tumor cells (as well as 4T1-HA)
grow as well as their AB1 (or 4T1) parental cells in
unmanipulated immunocompetent mice (Figure 1a). This
is not due to an insufficient number of Teffs that could
not counteract the natural Treg response. Indeed, the
injection of up to 9 10
6 HA-specific effectors, which is
410
3 times the frequency of highly represented specifi-
city,
35–37 can only slightly delay but cannot eradicate
AB1-HA tumor cells (Figure 3a). The rejection of AB1-
HA tumor cells in the presence of Tregs could only be
achieved with the injection of antigen-experienced T cells
(Figure 3b). The capacity of memory Teffs to escape
Treg-mediated suppression is mostly a question of
kinetics of responses. We indeed recently showed that
tumor emergence leads to a brisk recruitment and
activation of memory Tregs
19 that respond to self-
antigens with a memory type kinetic; in contrast,
antitumor Teffs that have never seen their cognate antigen
beforehand are recruited more slowly with a naive type
kinetic of the response. If memory Teffs are present, they
are recruited with the same memory kinetics than Tregs,
which are unable to control them. Besides the kinetics
of Treg vs Teff responses, memory effectors appear to
be somehow resistant to Treg-mediated suppression as
previously shown in auto-immune and transplantation
settings.
38,39
Thus, altogether, Treg manipulation will likely be
always required to generate efficient antitumor immune
responses, even in the presence of a potent antigen.
Immunodominance of tumor antigens restricts the breadth
of antitumor immune responses in the absence of Tregs
Although the presence of a potent antigen is advanta-
geous for the development of efficient antitumor immune
response in the absence of Tregs, it may also be
disadvantageous.
40 Indeed, we show that the presence of
a ‘too’ immunodominant TAA can strongly bias the
immune response toward this antigen, preventing the
development of a broader one. Although only a few mice
survived a challenge with the mesothelioma AB1 tumors
after Treg depletion, they could all resist to a second
challenge not only with the same tumor, but also to a
challenge with mammary carcinoma 4T1 tumor cells
(Figure 4b). In contrast, only 16.7% of the numerous
mice that survived an initial challenge with AB1-HA
tumor cells could resist a 4T1 challenge (Figure 4b). This
indicates that (1) the breadth of the anti-AB1 immune
responses covers some antigens that are shared by the 4T1
tumors and (2) the presence of HA onto the tumor
deviates the immune response against this dominant
antigen. However, subsequent challenges with HA-ex-
pressing tumors could increase immune response to
nondominant tumor antigens (Figure 5).
Cryptic/subdominant antigens are defined as self-
hindered epitopes, due to indolent or excessive processing
of protein. Therefore, T cells recognizing such epitopes
are not submitted to clonal deletion, which allow the
existence of reactive T-cell clones in the periphery.
Recognition of these epitopes by T-cell clones can lead
to their activation.
41 An ‘epitope spreading’ revealed by
the generation of immune responses to such cryptic/
subdominant antigens has indeed been shown (1) in
cancer models, with T-cell responses directed toward
distinct p53 peptides depending on the stage of tumor-
igenesis
42,43 or with peptide immunizations that yield
the generation of cytotoxic T cells against different
protein
44,45 or (2) in autoimmune models such as
experimental autoimmune encephalomyelitis or insulin-
dependent diabetes mellitus, under prolonged stimulation
with myelin basic protein or glutamic acid decarboxylase,
respectively.
46,47
Thus, a too important restriction of the antitumor
immune response would not allow the development of
responses toward existing cryptic/subdominant antigens;
this could favor immunoediting of the tumor, leading to
the appearance of escape variants by mutation of this
immunodominant antigen,
48–50 a process that would be
less likely to occur if the immune response breadth is
broader. Further analyses of antigens and major histo-
compatibility complex expression in tumors that grow out
despite previous successful response to a tumor challenge
would substantiate the occurrence of tumor escape
variants and point to its relevance for future therapies.
Implications for immunotherapy
Taken together, our results highlight that successful
immunotherapies will most likely be combinatorial,
controlling Tregs while stimulating Teffs. However, we
anticipate that such strategies should lead to improved
clinical responses only in a fraction of the patients.
Indeed, in treated inbred mice injected with the same
tumors, there is already heterogeneity of the tumor fate;
this indicates that the outcome of the battle between the
tumor cells and the immune system is multiparametric
Antigen quality and antitumor immune responses
A-S Bergot et al
651
Cancer Gene Therapyand uncertain, and thus likely to much vary between
heterogeneous patients. Ultimately, combination treat-
ments using the whole panoply of treatments—surgery,
chemotherapy, gene therapy, immunotherapy—are likely
to be required to treat cancer patients.
In this line, we have previously reported the results of a
clinical trial based on vaccination of patients with renal
cell carcinoma with autologous bone-marrow derived
dendritic cells sensitized with tumor lysates.
51 The out-
come was poor, in large part because we co-treated the
patients with interleukin-2 to attempt to better activate
effector responses,
52 while this cytokine is now known
as a Treg inducer. We also have an undergoing clinical
trial for patients with metastatic colorectal cancer in
which patients receive a lymphoablation, followed by
the reinjection of Treg-depleted T cells (STARTREK
ClinicalTrials.gov NCT00986518). We believe that on the
basis of our results, these two approaches could be
combined in the future, but with sensitizing dendritic cells
with tumor extract as well as with a strong colorectal
cancer tumor antigen such as carcinoembryonic antigen.
53
In conclusion, we believe that the manipulation of
Tregs should become an almost mandatory part of
multimodal cancer immunotherapy.
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